inclusion criteria: - signed informed consent must be obtained prior to participation in the study - diagnosis of relapsing ms by 2017 revised mcdonald criteria - willing to comply with the study schedule - will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab - eligible to receive and plan to be started on ofatumumab or currently on prescribed ofatumumab for ≥ 4 weeks or currently on commercially prescribed interferon or glatiramer acetate for ≥ 4 weeks

inclusion criteria: - signed informed consent must be obtained prior to participation in the study - diagnosis of relapsing ms by 2017 revised mcdonald criteria - willing to comply with the study schedule - will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab - eligible to receive and plan to be started on ofatumumab or currently on prescribed ofatumumab for ≥ 4 weeks or currently on commercially prescribed interferon or glatiramer acetate for ≥ 4 weeks